Short-term effectiveness and safety of ustekinumab and vedolizumab in elderly and non-elderly patients with Crohn's disease: a comparative study.

Autor:	Dar L; Department of Gastroenterology, Sheba Medical Center, Tel-Hashomer 52621, Israel., Shani U; Department of Gastroenterology, Sheba Medical Center, Tel-Hashomer, Israel.; Faculty of Medical and Health Sciences, Tel-Aviv University, Israel., Dotan A; Department of Gastroenterology, Sheba Medical Center, Tel-Hashomer, Israel.; Faculty of Medical and Health Sciences, Tel-Aviv University, Israel., Ukashi O; Department of Gastroenterology, Sheba Medical Center, Tel-Hashomer, Israel.; Faculty of Medical and Health Sciences, Tel-Aviv University, Israel., Ben-Horin S; Department of Gastroenterology, Sheba Medical Center, Tel-Hashomer, Israel.; Faculty of Medical and Health Sciences, Tel-Aviv University, Israel., Kopylov U; Department of Gastroenterology, Sheba Medical Center, Tel-Hashomer, Israel.; Faculty of Medical and Health Sciences, Tel-Aviv University, Israel., Levartovsky A; Department of Gastroenterology, Sheba Medical Center, Tel-Hashomer 52621, Israel.
Jazyk:	angličtina
Zdroj:	Therapeutic advances in gastroenterology [Therap Adv Gastroenterol] 2024 Nov 19; Vol. 17, pp. 17562848241299752. Date of Electronic Publication: 2024 Nov 19 (Print Publication: 2024).
DOI:	10.1177/17562848241299752
Abstrakt:	Background: Inflammatory bowel disease (IBD) presents unique challenges in elderly patients due to comorbidities and treatment-related risks. Objectives: This study evaluates ustekinumab (UST) and vedolizumab (VDZ) efficacy and safety in elderly Crohn's disease (CD) patients. Design: A retrospective cohort study at a tertiary medical center. Methods: CD patients aged ⩾60 years (elderly) treated with UST, compared to non-elderly (<60 years) patients treated with UST and elderly patients treated with VDZ. Clinical response was evaluated using the Harvey-Bradshaw index (HBI) and clinical biomarkers, alongside monitoring steroid use, hospitalization rates, treatment persistence, and surgical interventions. Results: The study included 166 CD patients: 32 elderly and 65 non-elderly patients treated with UST, and 69 elderly patients treated with VDZ. The mean duration of follow-up was 10.8 ± 2.8 months in the non-elderly group, 9.97 ± 3.28 months in the elderly UST group, and 10.0 ± 3.29 months in the VDZ group. Elderly UST patients were more likely to receive corticosteroids at initiation than non-elderly UST patients (44% vs 14%, p  = 0.001). At 12 months, clinical response rates did not significantly differ between elderly and non-elderly UST groups, respectively (48% vs 40%, p  = 0.5). However, elderly UST patients exhibited higher hospitalization rates over time compared to non-elderly UST patients (6-month: 19% vs 6.2%, p  = 0.077; 12-month: 19% vs 4.6%, p  = 0.055; log-rank p  = 0.004). No significant differences were observed in clinical response and remission rates between elderly UST and elderly VDZ patients at 6 and 12 months. At 6 months, a higher hospitalization rate was observed in the UST group (19% vs 4.3% p  = 0.027), but this difference did not persist over time. Conclusion: UST and VDZ are effective and safe treatments for elderly CD patients, despite higher hospitalization rates compared to non-elderly patients, likely due to age-related complications. Competing Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: U.K.: speaker and advisory fees: Abbvie, BMS, Celtrion, Elly Lili, Janssen, Medronic, Pfizer, Takeda, Roche, research support: Abbvie, Elly Lili, Jannsen, Medtronic, Takeda. S.B.-H.: advisory board and/or consulting fees: Abbvie, Takeda, Janssen, Celltrion, Pfizer, GSK, Ferring, Novartis, Roche, Gilead, NeoPharm, Predicta Med, Galmed, Medial Earlysign, BMS and Eli Lilli, holds stocks/options in Predicta Med, Evinature & Galmed, research support: Abbvie, Takeda, Janssen, Celltrion, Pfizer, & Galmed. The remaining authors declare that they have no conflicts of interest. (© The Author(s), 2024.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu